Adapted from this X-therma press release
Long-time Foundry industry users, X-therma, recently announced a successful, oversubscribed Series A funding round.
X-Therma develops novel, convergent chemical technologies in biopreservation to advance the field of regenerative medicine by making available safe and on-demand organs for transplant, engineered tissues, and cell therapies for the patients in need. They work with Foundry scientists to harness nature-inspired, non-toxic polymers to prevent ice formation during long term storage that solves the long-standing roadblock of cold storage and logistics. The Company is devoted to lead innovation that enables global Regenerative Medicines on-demand to improve modern medicine and save, repair & rejuvenate billions of lives from today to eternity.
“Founded with the mission to enable global organ banking, our platform technology has expanded to all living medicines. Biopreservation is crucial in the evolving regenerative medicine market. It underlies the sourcing of cellular material, manufacture, storage, and delivery of final products,” says Dr. Xiaoxi Wei, CEO & Co-Founder of X-Therma. “Since the onset of the pandemic, the demand for advanced biopharma cold chain solutions has become extremely hot. COVID vaccines have accelerated this growth and exposed cold-chain weaknesses. From day one, our vision has been focused on the heavy lifting of fundamental scientific breakthroughs to solve the soon-to-be bottlenecks still in existence due to a lack of innovation. Our technology supports cell and gene therapy CMC by greatly improving the critical cell preservation process that can make-or-break the delivery of a successful medicine.”
Interested in Becoming a Foundry User?
Join our collaborative, multidisciplinary environment.
Learn more >
With this new round of funding, the company plans to scale commercialization of XT-Thrive® to meet customer demand for cGMP-grade cell preservation products aimed at Cell and Gene Therapies and tissue engineering users in chemistry, manufacturing, and control processes. Moreover, through its continued partnership with Johns Hopkins University, X-Therma will expand collaboration efforts worldwide and accelerate the regulatory process for organ preservation.
